X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ALEMBIC PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ALEMBIC PHARMA DIVIS LABORATORIES/
ALEMBIC PHARMA
 
P/E (TTM) x 29.1 28.9 100.7% View Chart
P/BV x 5.0 6.6 76.5% View Chart
Dividend Yield % 1.0 0.7 137.5%  

Financials

 DIVIS LABORATORIES   ALEMBIC PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
ALEMBIC PHARMA
Mar-16
DIVIS LABORATORIES/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,222792 154.4%   
Low Rs784443 177.0%   
Sales per share (Unadj.) Rs153.1167.0 91.7%  
Earnings per share (Unadj.) Rs39.938.2 104.7%  
Cash flow per share (Unadj.) Rs44.642.0 106.2%  
Dividends per share (Unadj.) Rs10.004.00 250.0%  
Dividend yield (eoy) %1.00.6 153.9%  
Book value per share (Unadj.) Rs201.884.9 237.7%  
Shares outstanding (eoy) m265.47188.52 140.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.63.7 177.2%   
Avg P/E ratio x25.116.2 155.2%  
P/CF ratio (eoy) x22.514.7 153.0%  
Price / Book Value ratio x5.07.3 68.4%  
Dividend payout %25.010.5 238.8%   
Avg Mkt Cap Rs m266,266116,383 228.8%   
No. of employees `0009.7NA-   
Total wages/salary Rs m4,6874,214 111.2%   
Avg. sales/employee Rs Th4,175.0NM-  
Avg. wages/employee Rs Th481.5NM-  
Avg. net profit/employee Rs Th1,089.3NM-  
INCOME DATA
Net Sales Rs m40,64331,487 129.1%  
Other income Rs m74955 1,359.2%   
Total revenues Rs m41,39231,542 131.2%   
Gross profit Rs m14,46010,060 143.7%  
Depreciation Rs m1,233722 170.8%   
Interest Rs m2337 61.4%   
Profit before tax Rs m13,9539,356 149.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3492,160 155.0%   
Profit after tax Rs m10,6047,194 147.4%  
Gross profit margin %35.631.9 111.4%  
Effective tax rate %24.023.1 104.0%   
Net profit margin %26.122.8 114.2%  
BALANCE SHEET DATA
Current assets Rs m40,10515,066 266.2%   
Current liabilities Rs m6,5957,674 85.9%   
Net working cap to sales %82.523.5 351.2%  
Current ratio x6.12.0 309.8%  
Inventory Days Days11967 177.0%  
Debtors Days Days8141 198.6%  
Net fixed assets Rs m19,9958,237 242.7%   
Share capital Rs m531377 140.8%   
"Free" reserves Rs m53,04315,416 344.1%   
Net worth Rs m53,57416,005 334.7%   
Long term debt Rs m00-   
Total assets Rs m61,58524,594 250.4%  
Interest coverage x618.4255.2 242.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.71.3 51.5%   
Return on assets %17.329.4 58.7%  
Return on equity %19.844.9 44.0%  
Return on capital %26.158.7 44.5%  
Exports to sales %055.7 0.0%   
Imports to sales %25.210.4 242.1%   
Exports (fob) Rs mNA17,551 0.0%   
Imports (cif) Rs m10,2593,283 312.5%   
Fx inflow Rs m35,38417,811 198.7%   
Fx outflow Rs m10,3995,318 195.5%   
Net fx Rs m24,98512,493 200.0%   
CASH FLOW
From Operations Rs m11,4939,304 123.5%  
From Investments Rs m-11,372-3,105 366.3%  
From Financial Activity Rs m-93-1,959 4.8%  
Net Cashflow Rs m284,240 0.7%  

Share Holding

Indian Promoters % 52.0 74.1 70.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 2.9 406.9%  
FIIs % 19.0 9.1 208.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 13.9 123.7%  
Shareholders   31,796 49,328 64.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  STRIDES SHASUN LTD  J.B.CHEMICALS  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 22, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS